血液凈化在新型冠狀病毒感染中的應用_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

馮苗 ,  姚孟英

鄭州大學第一附屬醫院呼吸與危重癥醫學科三（河南鄭州 450003）;

Corresponding?author：

姚孟英, Email: zdyfyricu@qq.com

Keywords：

DOI：

10.7507/1671-6205.202310003

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 馮苗, 姚孟英. 血液凈化在新型冠狀病毒感染中的應用. Chinese Journal of Respiratory and Critical Care Medicine, 2024, 23(5): 359-364. doi: 10.7507/1671-6205.202310003 Copy

1.	Denning NL, Aziz M, Gurien SD, et al. DAMPs and NETs in sepsis. Front Immunol, 2019, 10: 2536.
2.	Frevert CW, Felgenhauer J, Wygrecka M, et al. Danger-associated molecular patterns derived from the extracellular matrix provide temporal control of innate immunity. J Histochem Cytochem, 2018, 66(4): 213-227.
3.	9th International Congress "sepsis and multiorgan dysfunction". Infection, 2019, 47(Suppl 1): 1-67.
4.	Ebeyer-Masotta M, Eichhorn T, Weiss R, et al. Heparin-functionalized adsorbents eliminate central effectors of immunothrombosis, including platelet factor 4, high-mobility group box 1 protein and histones. Int J Mol Sci, 2022, 23(3): 1823.
5.	McElvaney OJ, McEvoy NL, McElvaney OF, et al. Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med, 2020, 202(6): 812-821.
6.	中華醫學會腎臟病學分會, 中國研究型醫院學會腎臟病學專業委員會. 特殊血液凈化技術應用于重癥新型冠狀病毒肺炎的專家共識. 中華內科雜志, 2020, 59(11): 847-853.
7.	裴茂華, 王瑤, 陳倩, 等. 重型新型冠狀病毒肺炎的發病機制與血液凈化治療的應用. 中國中西醫結合急救雜志, 2020, 27(4): 499-501.
8.	Ronco C, Chawla L, Husain-Syed F, et al. Rationale for sequential extracorporeal therapy (SET) in sepsis. Crit Care, 2023, 27(1): 50.
9.	Jacobs JL, Bain W, Naqvi A, et al. Severe acute respiratory syndrome coronavirus 2 viremia is associated with coronavirus disease 2019 severity and predicts clinical outcomes. Clin Infect Dis, 2022, 74(9): 1525-1533.
10.	Seffer MT, Cottam D, Forni LG, et al. Heparin 20: a new approach to the infection crisis. Blood Purif, 2021, 50(1): 28-34.
11.	Olson SW, Oliver JD, Collen J, et al. Treatment for severe coronavirus disease 2019 with the seraph-100 Microbind Affinity Blood Filter. Crit Care Explor, 2020, 2(8): e0180.
12.	Axelsson J, Ferreira M, Adolfsson L, et al. Cytokines in blood from septic patients interact with surface-immobilized heparin. ASAIO J, 2010, 56(1): 48-51.
13.	López-Mu?oz AD, Kosik I, Holly J, et al. Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity. Sci Adv, 2022, 8(31): eabp9770.
14.	Kielstein JT, Borchina DN, Fühner T, et al. Hemofiltration with the Seraph? 100 Microbind? Affinity Filter decreases SARS-CoV-2 nucleocapsid protein in critically ill COVID-19 patients. Crit Care, 2021, 25(1): 190.
15.	Eden G, Schmidt JJ, Büttner S, et al. Safety and efficacy of the Seraph? 100 Microbind? Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study. Crit Care, 2022, 26(1): 181.
16.	Kelly MM, Wilkinson JD, Rastegar M, et al. Two patients with severe COVID pneumonia treated with the Seraph-100 Microbind Affinity Blood Filter. J Intensive Care Med, 2021, 36(10): 1228-1232.
17.	Chitty SA, Mobbs S, Rifkin BS, et al. A multicenter evaluation of the Seraph 100 Microbind Affinity Blood Filter for the treatment of severe COVID-19. Crit Care Explor, 2022, 4(4): e0662.
18.	Shadvar K, Tagizadiyeh A, Gamari AA, et al. Hemoperfusion as a potential treatment for critically ill COVID-19 patients with cytokine storm. Blood Purif, 2021, 50(3): 405-407.
19.	Surasit K, Srisawat N. The efficacy of early additional hemoperfusion therapy for severe COVID-19 patients: a prospective cohort study. Blood Purif, 2022, 51(11): 879-888.
20.	De Rosa S, Cutuli SL, Ferrer R, et al. COVID-19 EUPHAS2 Collaborative Group. Polymyxin B hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: case series from EUPHAS2 registry. Artif Organs, 2021, 45(6): E187-E194.
21.	Kuwana T, Kinoshita K, Ihara S, et al. The characteristics of patients with severe COVID-19 pneumonia treated with direct hemoperfusion using Polymyxin B-Immobilized Fiber Column (PMX-DHP). Infect Drug Resist, 2022, 15: 4819-4828.
22.	賀慧為, 夏文翰, 陳志, 等. 血液灌流吸附炎癥因子治療膿毒癥的療效分析. 中國呼吸與危重監護雜志, 2023, 22(1): 13-17.
23.	Kuwana T, Kinoshita K, Hirabayashi M, et al. PMX-DHP therapy for dyspnea and deoxygenation in severe COVID-19 pneumonia: a case series. Infect Drug Resist, 2021, 14: 1305-1310.
24.	Enomoto N, Suda T, Uto T, et al. Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX-DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia. Respirology, 2008, 13(3): 452-60.
25.	Chew CH, Huang WT, Yang TS, et al. Ultra-high packing density next generation microtube array membrane for absorption based applications. Membranes (Basel), 2021, 11(4): 273.
26.	Villa G, Romagnoli S, De Rosa S, et al. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study. Crit Care, 2020, 24(1): 605.
27.	Premu?i? V, Babel J, Gardijan D, et al. Extracorporeal blood purification is associated with improvement in biochemical and clinical variables in the critically-ill COVID-19 patients. Ther Apher Dial, 2022, 26(2): 316-329.
28.	Lim MX, Fong KK, Yeap TB. Use of extracorporeal blood purification therapy (ECBPT) as an adjuvant to high-dose corticosteroids in a severely ill COVID-19 patient with concomitant bacterial infection. BMJ Case Rep, 2021, 14(10): e245639.
29.	Wei S, Zhang Y, Zhai K, et al. CytoSorb in patients with coronavirus disease 2019: a rapid evidence review and meta-analysis. Front Immunol, 2023, 14: 1067214.
30.	Rieder M, Wengenmayer T, Staudacher D, et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation. Crit Care, 2020, 24(1): 435.
31.	Akil A, Napp LC, Rao C, et al. Use of CytoSorb? hemoadsorption in patients on Veno-Venous ECMO support for severe acute respiratory distress syndrome: a systematic review. J Clin Med, 2022, 11(20): 5990.
32.	Nassiri AA, Hakemi MS, Miri MM, et al. Blood puri?cation with cytosorb in critically ill covid-19 patients: a case series of 26 patients. Artif Organs, 2021, 45(11): 1338-1347.
33.	Damiani M, Gandini L, Landi F, et al. Extracorporeal cytokine hemadsorption in severe covid-19 respiratory failure. Respir Med, 2021, 185: 106477.
34.	曹文雅, 陳蕾, 薛瑾虹, 等. 應用oXiris濾器CRRT治療合并細胞因子風暴綜合征的危重癥COVID-19患者1例報告. 中華腎病研究電子雜志, 2022, 11(5): 297-299.
35.	Song T, Hayanga J, Durham L, et al. CytoSorb therapy in COVID-19 (CTC) patients requiring extracorporeal membrane oxygenation: a multicenter, retrospective registry. Front Med (Lausanne), 2021, 8: 773461.
36.	Supady A, Weber E, Rieder M, et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. Lancet Respir Med, 2021, 9(7): 755-762.
37.	Lebreton G, Dorgham K, Quentric P, et al. Longitudinal cytokine profiling in patients with severe covid-19 on extracorporeal membrane oxygenation and hemoadsorption. Am J Respir Crit Care Med, 2021, 203(11): 1433-14355.
38.	Ugurov P, Popevski D, Gramosli T, et al. Early initiation of extracorporeal blood purification using the AN69ST (oXiris?) hemofilter as a treatment modality for COVID-19 patients: a single-centre case series. Braz J Cardiovasc Surg, 2022, 37(1): 35-47.
39.	Schmidt JJ, Borchina DN, Van't Klooster M, et al. Interim analysis of the COSA (COVID-19 patients treated with the Seraph? 100 Microbind? Affinity filter) registry. Nephrol Dial Transplant, 2022, 37(4): 673-680.
40.	Kawazoe Y, Sato T, Miyagawa N, et al. Mortality effects of prolonged hemoperfusion therapy using a Polymyxin B-Immobilized fiber column for patients with septic shock: a sub-analysis of the DESIRE trial. Blood Purif, 2018, 46(4): 309-314.
41.	Mitaka C, Tsuchida N, Kawada K, et al. A longer duration of polymyxin B-immobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock. Shock, 2009, 32(5): 478-483.
42.	Miyamoto K, Kawazoe Y, Kato S. Prolonged direct hemoperfusion using a polymyxin B immobilized fiber cartridge provides sustained circulatory stabilization in patients with septic shock: a retrospective observational before-after study. J Intensive Care, 2017, 5: 19.
43.	Romaschin AD, Klein DJ, Marshall JC. Bench-to-bedside review: clinical experience with the endotoxin activity assay. Crit Care, 2012, 16(6): 248.
44.	Klein DJ, Foster D, Walker PM, et al. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med, 2018, 44(12): 2205-2212.
45.	Fujimori K, Tarasawa K, Fushimi K. Effects of polymyxin B hemoperfusion on septic shock patients requiring noradrenaline: analysis of a nationwide administrative database in Japan. Blood Purif, 2021, 50(4-5): 560-565.
46.	Fujimori K, Tarasawa K, Fushimi K. Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study. Ann Intensive Care, 2021, 11(1): 141.
47.	Pomarè Montin D, Ankawi G, Lorenzin A, et al. Biocompatibility and cytotoxic evaluation of new sorbent cartridges for blood hemoperfusion. Blood Purif, 2018, 46(3): 187-195.
48.	Lorenzin A, Neri M, de Cal M, et al. Fluid dynamics analysis by CT imaging technique of new sorbent cartridges for extracorporeal therapies. Blood Purif, 2019, 48(1): 18-24.
49.	Shimizu T, Miyake T, Tani M. History and current status of polymyxin B-immobilized fiber column for treatment of severe sepsis and septic shock. Ann Gastroenterol Surg, 2017, 1(2): 105-113.
50.	Rosalia RA, Ugurov P, Neziri D, et al. Extracorporeal blood purification in moderate and severe COVID-19 patients: a prospective cohort study. Blood Purif, 2022, 51(3): 233-242.
51.	Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost, 2020, 18(4): 844-847.
52.	Shimizu T, Miyake T, Kitamura N, et al. Endotoxin adsorption: direct hemoperfusion with the polymyxin B-immobilized fiber column (PMX). Transfus Apher Sci, 2017, 56(5): 682-688.
53.	Zhang L, Yan Tang GK, Liu S, et al. Hemofilter with adsorptive capacities: case report series. Blood Purif, 2019, 47 Suppl 3: 1-6.
54.	Schmidt JJ, Eden G, Seffer MT, et al. In vitro elimination of anti-infective drugs by the Seraph? 100 Microbind? affinity blood filter. Clin Kidney J, 2020, 13(3): 421-424.
55.	Schmidt JJ, Bode-B?ger SM, Martens-Lobenhoffer J, et al. Pharmacokinetics of Remdesivir and GS-441524 during PIRRT and Seraph 100 therapy. Clin J Am Soc Nephrol, 2021, 16(8): 1256-1257.
56.	de Geus HRH, Smeets T, Hoek RAS, et al. The Seraph?-100 Microbind Affinity Blood Filter does not affect Vancomycin, Tacrolimus, and Mycophenolic Acid plasma concentrations. Blood Purif, 2021, 50(6): 971-975.
57.	Seffer MT, Martens-Lobenhoffer J, Schmidt JJ, et al. Clearance of chloroquine and hydroxychloroquine by the Seraph? 100 Microbinda Affinity Blood Filter -a device approved for the treatment of COVID-19 patients. Ther Apher Dial, 2021, 25(2): 237-241.
58.	Lorenzin A, de Cal M, Marcello M, et al. Vancomycin adsorption during in vitro model of hemoperfusion with mini-module of HA380 cartridge. Blood Purif, 2023, 52(2): 174-182.
59.	Shimokawa K, Takakuwa R, Wada Y, et al. Adsorption of various antimicrobial agents to endotoxin removal polymyxin-B immobilized fiber (Toraymyxin?). Part 2: adsorption of two drugs to Toraymyxin PMX-20R cartridges. Colloids Surf B Biointerfaces, 2013, 101: 350-352.
60.	Scheier J, Nelson PJ, Schneider A, et al. Mechanistic Considerations and pharmacokinetic implications on concomitant drug administration during CytoSorb therapy. Crit Care Explor, 2022, 4(5): e0688.
61.	Lewis TC, Merchan C, Toy B, et al. Impact of CytoSorb hemoadsorption on sedation requirements in patients with severe COVID-19 on Venovenous Extracorporeal Membrane Oxygenation. ASAIO J, 2021, 67(8): 856-861.
62.	Selig DJ, Reed T, Chung KK, et al. Hemoperfusion with Seraph 100 Microbind Affinity Blood Filter unlikely to require increased antibiotic dosing: a simulations study using a pharmacokinetic/pharmacodynamic approach. Blood Purif, 2023, 52(1): 25-31.

1. Denning NL, Aziz M, Gurien SD, et al. DAMPs and NETs in sepsis. Front Immunol, 2019, 10: 2536.
2. Frevert CW, Felgenhauer J, Wygrecka M, et al. Danger-associated molecular patterns derived from the extracellular matrix provide temporal control of innate immunity. J Histochem Cytochem, 2018, 66(4): 213-227.
3. 9th International Congress "sepsis and multiorgan dysfunction". Infection, 2019, 47(Suppl 1): 1-67.
4. Ebeyer-Masotta M, Eichhorn T, Weiss R, et al. Heparin-functionalized adsorbents eliminate central effectors of immunothrombosis, including platelet factor 4, high-mobility group box 1 protein and histones. Int J Mol Sci, 2022, 23(3): 1823.
5. McElvaney OJ, McEvoy NL, McElvaney OF, et al. Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med, 2020, 202(6): 812-821.
6. 中華醫學會腎臟病學分會, 中國研究型醫院學會腎臟病學專業委員會. 特殊血液凈化技術應用于重癥新型冠狀病毒肺炎的專家共識. 中華內科雜志, 2020, 59(11): 847-853.
7. 裴茂華, 王瑤, 陳倩, 等. 重型新型冠狀病毒肺炎的發病機制與血液凈化治療的應用. 中國中西醫結合急救雜志, 2020, 27(4): 499-501.
8. Ronco C, Chawla L, Husain-Syed F, et al. Rationale for sequential extracorporeal therapy (SET) in sepsis. Crit Care, 2023, 27(1): 50.
9. Jacobs JL, Bain W, Naqvi A, et al. Severe acute respiratory syndrome coronavirus 2 viremia is associated with coronavirus disease 2019 severity and predicts clinical outcomes. Clin Infect Dis, 2022, 74(9): 1525-1533.
10. Seffer MT, Cottam D, Forni LG, et al. Heparin 20: a new approach to the infection crisis. Blood Purif, 2021, 50(1): 28-34.
11. Olson SW, Oliver JD, Collen J, et al. Treatment for severe coronavirus disease 2019 with the seraph-100 Microbind Affinity Blood Filter. Crit Care Explor, 2020, 2(8): e0180.
12. Axelsson J, Ferreira M, Adolfsson L, et al. Cytokines in blood from septic patients interact with surface-immobilized heparin. ASAIO J, 2010, 56(1): 48-51.
13. López-Mu?oz AD, Kosik I, Holly J, et al. Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity. Sci Adv, 2022, 8(31): eabp9770.
14. Kielstein JT, Borchina DN, Fühner T, et al. Hemofiltration with the Seraph? 100 Microbind? Affinity Filter decreases SARS-CoV-2 nucleocapsid protein in critically ill COVID-19 patients. Crit Care, 2021, 25(1): 190.
15. Eden G, Schmidt JJ, Büttner S, et al. Safety and efficacy of the Seraph? 100 Microbind? Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study. Crit Care, 2022, 26(1): 181.
16. Kelly MM, Wilkinson JD, Rastegar M, et al. Two patients with severe COVID pneumonia treated with the Seraph-100 Microbind Affinity Blood Filter. J Intensive Care Med, 2021, 36(10): 1228-1232.
17. Chitty SA, Mobbs S, Rifkin BS, et al. A multicenter evaluation of the Seraph 100 Microbind Affinity Blood Filter for the treatment of severe COVID-19. Crit Care Explor, 2022, 4(4): e0662.
18. Shadvar K, Tagizadiyeh A, Gamari AA, et al. Hemoperfusion as a potential treatment for critically ill COVID-19 patients with cytokine storm. Blood Purif, 2021, 50(3): 405-407.
19. Surasit K, Srisawat N. The efficacy of early additional hemoperfusion therapy for severe COVID-19 patients: a prospective cohort study. Blood Purif, 2022, 51(11): 879-888.
20. De Rosa S, Cutuli SL, Ferrer R, et al. COVID-19 EUPHAS2 Collaborative Group. Polymyxin B hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: case series from EUPHAS2 registry. Artif Organs, 2021, 45(6): E187-E194.
21. Kuwana T, Kinoshita K, Ihara S, et al. The characteristics of patients with severe COVID-19 pneumonia treated with direct hemoperfusion using Polymyxin B-Immobilized Fiber Column (PMX-DHP). Infect Drug Resist, 2022, 15: 4819-4828.
22. 賀慧為, 夏文翰, 陳志, 等. 血液灌流吸附炎癥因子治療膿毒癥的療效分析. 中國呼吸與危重監護雜志, 2023, 22(1): 13-17.
23. Kuwana T, Kinoshita K, Hirabayashi M, et al. PMX-DHP therapy for dyspnea and deoxygenation in severe COVID-19 pneumonia: a case series. Infect Drug Resist, 2021, 14: 1305-1310.
24. Enomoto N, Suda T, Uto T, et al. Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX-DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia. Respirology, 2008, 13(3): 452-60.
25. Chew CH, Huang WT, Yang TS, et al. Ultra-high packing density next generation microtube array membrane for absorption based applications. Membranes (Basel), 2021, 11(4): 273.
26. Villa G, Romagnoli S, De Rosa S, et al. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study. Crit Care, 2020, 24(1): 605.
27. Premu?i? V, Babel J, Gardijan D, et al. Extracorporeal blood purification is associated with improvement in biochemical and clinical variables in the critically-ill COVID-19 patients. Ther Apher Dial, 2022, 26(2): 316-329.
28. Lim MX, Fong KK, Yeap TB. Use of extracorporeal blood purification therapy (ECBPT) as an adjuvant to high-dose corticosteroids in a severely ill COVID-19 patient with concomitant bacterial infection. BMJ Case Rep, 2021, 14(10): e245639.
29. Wei S, Zhang Y, Zhai K, et al. CytoSorb in patients with coronavirus disease 2019: a rapid evidence review and meta-analysis. Front Immunol, 2023, 14: 1067214.
30. Rieder M, Wengenmayer T, Staudacher D, et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation. Crit Care, 2020, 24(1): 435.
31. Akil A, Napp LC, Rao C, et al. Use of CytoSorb? hemoadsorption in patients on Veno-Venous ECMO support for severe acute respiratory distress syndrome: a systematic review. J Clin Med, 2022, 11(20): 5990.
32. Nassiri AA, Hakemi MS, Miri MM, et al. Blood puri?cation with cytosorb in critically ill covid-19 patients: a case series of 26 patients. Artif Organs, 2021, 45(11): 1338-1347.
33. Damiani M, Gandini L, Landi F, et al. Extracorporeal cytokine hemadsorption in severe covid-19 respiratory failure. Respir Med, 2021, 185: 106477.
34. 曹文雅, 陳蕾, 薛瑾虹, 等. 應用oXiris濾器CRRT治療合并細胞因子風暴綜合征的危重癥COVID-19患者1例報告. 中華腎病研究電子雜志, 2022, 11(5): 297-299.
35. Song T, Hayanga J, Durham L, et al. CytoSorb therapy in COVID-19 (CTC) patients requiring extracorporeal membrane oxygenation: a multicenter, retrospective registry. Front Med (Lausanne), 2021, 8: 773461.
36. Supady A, Weber E, Rieder M, et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. Lancet Respir Med, 2021, 9(7): 755-762.
37. Lebreton G, Dorgham K, Quentric P, et al. Longitudinal cytokine profiling in patients with severe covid-19 on extracorporeal membrane oxygenation and hemoadsorption. Am J Respir Crit Care Med, 2021, 203(11): 1433-14355.
38. Ugurov P, Popevski D, Gramosli T, et al. Early initiation of extracorporeal blood purification using the AN69ST (oXiris?) hemofilter as a treatment modality for COVID-19 patients: a single-centre case series. Braz J Cardiovasc Surg, 2022, 37(1): 35-47.
39. Schmidt JJ, Borchina DN, Van't Klooster M, et al. Interim analysis of the COSA (COVID-19 patients treated with the Seraph? 100 Microbind? Affinity filter) registry. Nephrol Dial Transplant, 2022, 37(4): 673-680.
40. Kawazoe Y, Sato T, Miyagawa N, et al. Mortality effects of prolonged hemoperfusion therapy using a Polymyxin B-Immobilized fiber column for patients with septic shock: a sub-analysis of the DESIRE trial. Blood Purif, 2018, 46(4): 309-314.
41. Mitaka C, Tsuchida N, Kawada K, et al. A longer duration of polymyxin B-immobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock. Shock, 2009, 32(5): 478-483.
42. Miyamoto K, Kawazoe Y, Kato S. Prolonged direct hemoperfusion using a polymyxin B immobilized fiber cartridge provides sustained circulatory stabilization in patients with septic shock: a retrospective observational before-after study. J Intensive Care, 2017, 5: 19.
43. Romaschin AD, Klein DJ, Marshall JC. Bench-to-bedside review: clinical experience with the endotoxin activity assay. Crit Care, 2012, 16(6): 248.
44. Klein DJ, Foster D, Walker PM, et al. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med, 2018, 44(12): 2205-2212.
45. Fujimori K, Tarasawa K, Fushimi K. Effects of polymyxin B hemoperfusion on septic shock patients requiring noradrenaline: analysis of a nationwide administrative database in Japan. Blood Purif, 2021, 50(4-5): 560-565.
46. Fujimori K, Tarasawa K, Fushimi K. Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study. Ann Intensive Care, 2021, 11(1): 141.
47. Pomarè Montin D, Ankawi G, Lorenzin A, et al. Biocompatibility and cytotoxic evaluation of new sorbent cartridges for blood hemoperfusion. Blood Purif, 2018, 46(3): 187-195.
48. Lorenzin A, Neri M, de Cal M, et al. Fluid dynamics analysis by CT imaging technique of new sorbent cartridges for extracorporeal therapies. Blood Purif, 2019, 48(1): 18-24.
49. Shimizu T, Miyake T, Tani M. History and current status of polymyxin B-immobilized fiber column for treatment of severe sepsis and septic shock. Ann Gastroenterol Surg, 2017, 1(2): 105-113.
50. Rosalia RA, Ugurov P, Neziri D, et al. Extracorporeal blood purification in moderate and severe COVID-19 patients: a prospective cohort study. Blood Purif, 2022, 51(3): 233-242.
51. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost, 2020, 18(4): 844-847.
52. Shimizu T, Miyake T, Kitamura N, et al. Endotoxin adsorption: direct hemoperfusion with the polymyxin B-immobilized fiber column (PMX). Transfus Apher Sci, 2017, 56(5): 682-688.
53. Zhang L, Yan Tang GK, Liu S, et al. Hemofilter with adsorptive capacities: case report series. Blood Purif, 2019, 47 Suppl 3: 1-6.
54. Schmidt JJ, Eden G, Seffer MT, et al. In vitro elimination of anti-infective drugs by the Seraph? 100 Microbind? affinity blood filter. Clin Kidney J, 2020, 13(3): 421-424.
55. Schmidt JJ, Bode-B?ger SM, Martens-Lobenhoffer J, et al. Pharmacokinetics of Remdesivir and GS-441524 during PIRRT and Seraph 100 therapy. Clin J Am Soc Nephrol, 2021, 16(8): 1256-1257.
56. de Geus HRH, Smeets T, Hoek RAS, et al. The Seraph?-100 Microbind Affinity Blood Filter does not affect Vancomycin, Tacrolimus, and Mycophenolic Acid plasma concentrations. Blood Purif, 2021, 50(6): 971-975.
57. Seffer MT, Martens-Lobenhoffer J, Schmidt JJ, et al. Clearance of chloroquine and hydroxychloroquine by the Seraph? 100 Microbinda Affinity Blood Filter -a device approved for the treatment of COVID-19 patients. Ther Apher Dial, 2021, 25(2): 237-241.
58. Lorenzin A, de Cal M, Marcello M, et al. Vancomycin adsorption during in vitro model of hemoperfusion with mini-module of HA380 cartridge. Blood Purif, 2023, 52(2): 174-182.
59. Shimokawa K, Takakuwa R, Wada Y, et al. Adsorption of various antimicrobial agents to endotoxin removal polymyxin-B immobilized fiber (Toraymyxin?). Part 2: adsorption of two drugs to Toraymyxin PMX-20R cartridges. Colloids Surf B Biointerfaces, 2013, 101: 350-352.
60. Scheier J, Nelson PJ, Schneider A, et al. Mechanistic Considerations and pharmacokinetic implications on concomitant drug administration during CytoSorb therapy. Crit Care Explor, 2022, 4(5): e0688.
61. Lewis TC, Merchan C, Toy B, et al. Impact of CytoSorb hemoadsorption on sedation requirements in patients with severe COVID-19 on Venovenous Extracorporeal Membrane Oxygenation. ASAIO J, 2021, 67(8): 856-861.
62. Selig DJ, Reed T, Chung KK, et al. Hemoperfusion with Seraph 100 Microbind Affinity Blood Filter unlikely to require increased antibiotic dosing: a simulations study using a pharmacokinetic/pharmacodynamic approach. Blood Purif, 2023, 52(1): 25-31.

Previous Article
低分子量肝素鈣注射液致彌漫性肺泡出血一例
Next Article
通氣比在急性呼吸窘迫綜合征患者中的應用進展

Chinese Journal of Respiratory and Critical Care Medicine

血液凈化在新型冠狀病毒感染中的應用

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content